# Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial

> **NCT06481566** · NA · RECRUITING · sponsor: **Chongqing University Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **RADIATION:** stereotactic ablative body radiotherapy

## Key facts

- **NCT ID:** NCT06481566
- **Lead sponsor:** Chongqing University Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-21
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06481566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06481566, "Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06481566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*